Cargando…

First experience with MR-guided focused ultrasound in the treatment of Parkinson's disease

BACKGROUND: Radiofrequency (RF) subthalamotomies have been proposed since the 1960s to treat patients suffering from Parkinson's disease (PD). Recently, the magnetic resonance (MR)-guided focused ultrasound technology (MRgFUS) offers the possibility to perform subthalamic thermocoagulations wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Magara, Anouk, Bühler, Robert, Moser, David, Kowalski, Milek, Pourtehrani, Payam, Jeanmonod, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4266014/
https://www.ncbi.nlm.nih.gov/pubmed/25512869
http://dx.doi.org/10.1186/2050-5736-2-11
_version_ 1782348963936993280
author Magara, Anouk
Bühler, Robert
Moser, David
Kowalski, Milek
Pourtehrani, Payam
Jeanmonod, Daniel
author_facet Magara, Anouk
Bühler, Robert
Moser, David
Kowalski, Milek
Pourtehrani, Payam
Jeanmonod, Daniel
author_sort Magara, Anouk
collection PubMed
description BACKGROUND: Radiofrequency (RF) subthalamotomies have been proposed since the 1960s to treat patients suffering from Parkinson's disease (PD). Recently, the magnetic resonance (MR)-guided focused ultrasound technology (MRgFUS) offers the possibility to perform subthalamic thermocoagulations with reduced risks and optimized accuracy. We describe here the initial results of the MRgFUS pallidothalamic tractotomy (PTT), an anatomical and physiological update of the earlier subthalamotomies. METHODS: Thirteen consecutive patients suffering from chronic (mean disease duration 9.7 years) and therapy-resistant PD were treated unilaterally with an MRgFUS PTT. Primary relief assessment indicators were the score reduction of the Unified Parkinson Disease Rating Scale (UPDRS) and the patient estimation of global symptom relief (GSR) taken at 3 months follow-up. Final temperatures at target were between 52°C and 59°C. The MR examinations were performed before the treatment, 2 days and 3 months after it. The accuracy of the targeting was calculated on 2 days post-treatment MR pictures for each PTT lesion. RESULTS: The first four patients received a PTT using the lesional parameters applied for thalamotomies. They experienced clear-cut recurrences at 3 months (mean UPDRS relief 7.6%, mean GSR 22.5%), and their MR showed no sign of thermal lesion in T2-weighted (T2w) images. As a consequence, the treatment protocol was adapted for the following nine patients by applying repetition of the final temperatures 4 to 5 times. That produced thermocoagulations of larger volumes (172 mm(3) against 83 mm(3) for the first four patients), which remained visible at 3 months on T2w images. These nine patients enjoyed a mean UPDRS reduction of 60.9% and a GSR of 56.7%, very close to the results obtained with radiofrequency lesioning. The targeting accuracy for the whole patient group was 0.5, 0.5, and 0.6 mm for the anteroposterior (AP), mediolateral (ML), and dorsoventral (DV) dimensions, respectively. CONCLUSIONS: This study demonstrated the feasibility, safety, and accuracy of the MRgFUS PTT. To obtain similar results as the ones of RF PTT, it was necessary to integrate the fact that white matter, in this case, the pallidothalamic tract, requires repeated thermal exposition to achieve full lesioning and thus full therapeutic effect.
format Online
Article
Text
id pubmed-4266014
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42660142014-12-16 First experience with MR-guided focused ultrasound in the treatment of Parkinson's disease Magara, Anouk Bühler, Robert Moser, David Kowalski, Milek Pourtehrani, Payam Jeanmonod, Daniel J Ther Ultrasound Research BACKGROUND: Radiofrequency (RF) subthalamotomies have been proposed since the 1960s to treat patients suffering from Parkinson's disease (PD). Recently, the magnetic resonance (MR)-guided focused ultrasound technology (MRgFUS) offers the possibility to perform subthalamic thermocoagulations with reduced risks and optimized accuracy. We describe here the initial results of the MRgFUS pallidothalamic tractotomy (PTT), an anatomical and physiological update of the earlier subthalamotomies. METHODS: Thirteen consecutive patients suffering from chronic (mean disease duration 9.7 years) and therapy-resistant PD were treated unilaterally with an MRgFUS PTT. Primary relief assessment indicators were the score reduction of the Unified Parkinson Disease Rating Scale (UPDRS) and the patient estimation of global symptom relief (GSR) taken at 3 months follow-up. Final temperatures at target were between 52°C and 59°C. The MR examinations were performed before the treatment, 2 days and 3 months after it. The accuracy of the targeting was calculated on 2 days post-treatment MR pictures for each PTT lesion. RESULTS: The first four patients received a PTT using the lesional parameters applied for thalamotomies. They experienced clear-cut recurrences at 3 months (mean UPDRS relief 7.6%, mean GSR 22.5%), and their MR showed no sign of thermal lesion in T2-weighted (T2w) images. As a consequence, the treatment protocol was adapted for the following nine patients by applying repetition of the final temperatures 4 to 5 times. That produced thermocoagulations of larger volumes (172 mm(3) against 83 mm(3) for the first four patients), which remained visible at 3 months on T2w images. These nine patients enjoyed a mean UPDRS reduction of 60.9% and a GSR of 56.7%, very close to the results obtained with radiofrequency lesioning. The targeting accuracy for the whole patient group was 0.5, 0.5, and 0.6 mm for the anteroposterior (AP), mediolateral (ML), and dorsoventral (DV) dimensions, respectively. CONCLUSIONS: This study demonstrated the feasibility, safety, and accuracy of the MRgFUS PTT. To obtain similar results as the ones of RF PTT, it was necessary to integrate the fact that white matter, in this case, the pallidothalamic tract, requires repeated thermal exposition to achieve full lesioning and thus full therapeutic effect. BioMed Central 2014-05-31 /pmc/articles/PMC4266014/ /pubmed/25512869 http://dx.doi.org/10.1186/2050-5736-2-11 Text en Copyright © 2014 Magara et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Magara, Anouk
Bühler, Robert
Moser, David
Kowalski, Milek
Pourtehrani, Payam
Jeanmonod, Daniel
First experience with MR-guided focused ultrasound in the treatment of Parkinson's disease
title First experience with MR-guided focused ultrasound in the treatment of Parkinson's disease
title_full First experience with MR-guided focused ultrasound in the treatment of Parkinson's disease
title_fullStr First experience with MR-guided focused ultrasound in the treatment of Parkinson's disease
title_full_unstemmed First experience with MR-guided focused ultrasound in the treatment of Parkinson's disease
title_short First experience with MR-guided focused ultrasound in the treatment of Parkinson's disease
title_sort first experience with mr-guided focused ultrasound in the treatment of parkinson's disease
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4266014/
https://www.ncbi.nlm.nih.gov/pubmed/25512869
http://dx.doi.org/10.1186/2050-5736-2-11
work_keys_str_mv AT magaraanouk firstexperiencewithmrguidedfocusedultrasoundinthetreatmentofparkinsonsdisease
AT buhlerrobert firstexperiencewithmrguidedfocusedultrasoundinthetreatmentofparkinsonsdisease
AT moserdavid firstexperiencewithmrguidedfocusedultrasoundinthetreatmentofparkinsonsdisease
AT kowalskimilek firstexperiencewithmrguidedfocusedultrasoundinthetreatmentofparkinsonsdisease
AT pourtehranipayam firstexperiencewithmrguidedfocusedultrasoundinthetreatmentofparkinsonsdisease
AT jeanmonoddaniel firstexperiencewithmrguidedfocusedultrasoundinthetreatmentofparkinsonsdisease